Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180799 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
A Phase 1 study of Melanoma and NSCLC, sponsored by BioAtla.
- Active
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 12
- Study locations
NCT05180799 is a Phase 1 study of Melanoma and NSCLC that is active but no longer recruiting, run by BioAtla. The registered enrollment target is 320 participants, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (55% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT05180799, a Phase 1 study of Melanoma and NSCLC, is active but no longer recruiting, sponsored by BioAtla.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 12
- Study locations
Study Summary
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Nivolumab
- BIOLOGICAL BA3071
- DRUG Pemetrexed (Alimta)
Study Locations (12)
California
- The Angeles Clinic and Research Institute - Los Angeles
- USC Norris Comprehensive Cancer Center - Los Angeles
New South Wales
- Border Medical Oncology Research Unit at Albury Wodonga Regional Cancer Centre - Albury
- Cancer Care Foundation - Miranda
Georgia
- Piedmont West - Atlanta
Indiana
- Northwest Cancer Centers - Dyer
New Jersey
- Morristown Medical Center/Atlantic Health System - Morristown
New York
- Icahn School of Medicine at Mt. Sinai - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Oregon
- Providence Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05180799
The ClinicalTrials.gov registry entry for NCT05180799 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (55% lower). The listed sponsor is BioAtla, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05180799 reports 12 study locations spanning 10 distinct geographic areas - top geographies include California, New South Wales, Georgia.
Frequently Asked Questions
What is clinical trial NCT05180799 about?
NCT05180799 is a clinical study titled "A Phase 1/2 Study of BA3071 in Patients With Solid Tumors". The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
What is the current status of trial NCT05180799?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2022-08-03. Estimated completion is 2026-06-30.
What conditions does trial NCT05180799 study?
This clinical trial studies the following conditions: Melanoma, NSCLC.
What interventions are being tested in trial NCT05180799?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Nivolumab (BIOLOGICAL), BA3071 (BIOLOGICAL), Pemetrexed (Alimta) (DRUG).
Who is sponsoring clinical trial NCT05180799?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05180799 being conducted?
This trial has 12 study locations across California, Georgia, Indiana, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.